Methicillin-resistant Staphylococcus aureus in Stockholm, Sweden: Molecular epidemiology and antimicrobial susceptibilities to ceftaroline, linezolid, mupirocin and vancomycin in 2014.

[1]  J. Ambler,et al.  Molecular characterization of MRSA isolates bracketing the current EUCAST ceftaroline-susceptible breakpoint for Staphylococcus aureus: the role of PBP2a in the activity of ceftaroline. , 2015, The Journal of antimicrobial chemotherapy.

[2]  D. Marriott,et al.  Non-susceptibility to ceftaroline in healthcare-associated multiresistant MRSA in Eastern Australia. , 2015, The Journal of antimicrobial chemotherapy.

[3]  P. V. van Genderen,et al.  Skin and soft tissue infections in intercontinental travellers and the import of multi-resistant Staphylococcus aureus to Europe. , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[4]  Ronald N. Jones,et al.  Ceftaroline Activity against Bacterial Pathogens Frequently Isolated in U.S. Medical Centers: Results from Five Years of the AWARE Surveillance Program , 2015, Antimicrobial Agents and Chemotherapy.

[5]  A. Mellmann,et al.  Staphylococcus aureus spa type t437: identification of the most dominant community-associated clone from Asia across Europe. , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[6]  V. Kos,et al.  Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective. , 2014, The Journal of antimicrobial chemotherapy.

[7]  M. Ramirez,et al.  Epidemiological survey of the first case of vancomycin-resistant Staphylococcus aureus infection in Europe , 2014, Epidemiology and Infection.

[8]  Ronald N. Jones,et al.  Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms. , 2014, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[9]  S. Richter,et al.  Continued Emergence of USA300 Methicillin-Resistant Staphylococcus aureus in the United States: Results from a Nationwide Surveillance Study , 2014, Infection Control & Hospital Epidemiology.

[10]  S. Richter,et al.  Activities of Vancomycin, Ceftaroline, and Mupirocin against Staphylococcus aureus Isolates Collected in a 2011 National Surveillance Study in the United States , 2013, Antimicrobial Agents and Chemotherapy.

[11]  Daniel M. Saman,et al.  A Perspective on How the United States Fell behind Northern Europe in the Battle against Methicillin-Resistant Staphylococcus aureus , 2013, Antimicrobial Agents and Chemotherapy.

[12]  F. Doucet-Populaire,et al.  Prevalence of mupirocin resistance among invasive coagulase-negative staphylococci and methicillin-resistant Staphylococcus aureus (MRSA) in France: emergence of a mupirocin-resistant MRSA clone harbouring mupA. , 2013, The Journal of antimicrobial chemotherapy.

[13]  M. Ramirez,et al.  First case of infection with vancomycin-resistant Staphylococcus aureus in Europe , 2013, The Lancet.

[14]  Ronald N. Jones,et al.  Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline. , 2012, The Journal of antimicrobial chemotherapy.

[15]  Ronald N. Jones,et al.  Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study. , 2010, The Journal of antimicrobial chemotherapy.

[16]  F. Hu,et al.  Prevalence of clinical meticillin-resistant Staphylococcus aureus (MRSA) with high-level mupirocin resistance in Shanghai and Wenzhou, China. , 2010, International journal of antimicrobial agents.

[17]  F. Tenover,et al.  Methicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiology. , 2009, The Journal of antimicrobial chemotherapy.

[18]  C. Nord,et al.  Genetic diversity of community-associated methicillin-resistant Staphylococcus aureus in southern Stockholm, 2000-2005. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[19]  J. Patel,et al.  Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  M. Loeb,et al.  Mupirocin-Resistant, Methicillin-Resistant Staphylococcus aureus Strains in Canadian Hospitals , 2007, Antimicrobial Agents and Chemotherapy.

[21]  J. Rothgänger,et al.  Typing of Methicillin-Resistant Staphylococcus aureus in a University Hospital Setting by Using Novel Software for spa Repeat Determination and Database Management , 2003, Journal of Clinical Microbiology.

[22]  K. Bowker,et al.  Vancomycin-resistant Staphylococcus aureus , 1998, The Lancet.

[23]  K. McConeghy,et al.  Methicillin-resistant Staphylococcus aureus therapy: past, present, and future. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  H. Boucher,et al.  Epidemiology of methicillin-resistant Staphylococcus aureus. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  G. Hedin,et al.  Epidemiology of methicillin-resistant Staphylococcus aureus in Southern Stockholm, 2000-2003. , 2007, Microbial drug resistance.